KIF26B and hepatocellular carcinoma: So far, there was only one research demonstrated that KIF26B participated in PI3K/Akt signaling regulation in HCC, silencing of KIF26B inhibited PI3K/Akt activation by reducing expression of mTOR, p-PI3K, and p-Akt, thereby suppressing the malignant properties of cancer cells.